Life Science Cluster
The main hub of this cluster is the Bio-Technopark, which was founded in 2003 in Schlieren, a suburb of Zurich. Nowadays, around 40 start-ups and established firms that develop new drugs, implants and diagnostic equipment are domiciled here. The great attraction of this site is mainly due to the fact that besides office space, specialized laboratory infrastructure – something that most start-ups would not be able to afford – can be rented here. The technological park is also an important place for building up business networks between industry, academia and research; start-up firms can find national and international start-up promoters, academic faculties, representatives from the world of politics, and conventions.
The Bio-Technopark can already lay claim to many sensational success stories. For example, the ETH spin-off, Glycart, which started off here, was sold to Roche for CHF 235 million. The medication, Gazyva, was developed under the name Glycart Roche. This drug is approved in the USA with a “Breakthrough Therapy” status and supports the treatment of therapy-resistant chronic lymphatic leukemia.